There is evidence that inflammatory processes may play a key role during surgical myocardial
reperfusion. The hypothesis of this study is that colchicine, an anti-inflammatory agent, may
lead to reduction in periprocedural infarct size, when administered during elective coronary
artery bypass graft surgery.